PMID- 9764044
OWN - NLM
STAT- MEDLINE
DCOM- 19981013
LR  - 20201209
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 43 Suppl 1
IP  - Suppl 1
DP  - 1998 Jul
TI  - The European meeting on Helicobacter pylori: therapeutic news from Lisbon.
PG  - S66-9
AB  - The current standard of Helicobacter pylori treatment has been confirmed by the 
      studies presented at the Lisbon workshop--that is, one of three one week proton 
      pump inhibitor (PPI) based triple therapies comprising a twice daily standard 
      dose of a PPI in combination with two of the following antimicrobial agents: 
      clarithromycin, amoxycillin, or a nitromidazole. This standard of treatment is 
      also highly efficacious and cost-effective in routine community practice. The 
      current data confirm the equivalence of ranitidine bismuth citrate to PPI, and of 
      azithromycin to clarithromycin. The optimum dose for azithromycin has not yet 
      been defined. There is some evidence that in certain regions treatment for more 
      than one week may be advantageous. The reasons are still not clear. However, 
      microbial resistance may be one important factor, as it has a substantial effect 
      on treatment outcome and the prevalence of resistance varies considerably in 
      different areas. The negative impact of resistance is increased by shortening the 
      treatment time. At present, there is no general necessity to test for resistance 
      before treatment. However, before selection of a second line treatment, testing 
      for resistance is recommended.
FAU - Peitz, U
AU  - Peitz U
AD  - Department of Gastroenterology, Hepatology and Infectiology, Otto-von 
      Guericke-University Magdeburg, Germany.
FAU - Menegatti, M
AU  - Menegatti M
FAU - Vaira, D
AU  - Vaira D
FAU - Malfertheiner, P
AU  - Malfertheiner P
LA  - eng
PT  - Congress
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Proton Pump Inhibitors)
RN  - 884KT10YB7 (Ranitidine)
RN  - HS813P8QPX (bismuth tripotassium dicitrate)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - *Anti-Bacterial Agents
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Bismuth/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination/*therapeutic use
MH  - Gastritis/drug therapy/*microbiology
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Organometallic Compounds/therapeutic use
MH  - Portugal
MH  - *Proton Pump Inhibitors
MH  - Ranitidine/*therapeutic use
PMC - PMC1766600
EDAT- 1998/10/09 00:00
MHDA- 1998/10/09 00:01
PMCR- 2001/07/01
CRDT- 1998/10/09 00:00
PHST- 1998/10/09 00:00 [pubmed]
PHST- 1998/10/09 00:01 [medline]
PHST- 1998/10/09 00:00 [entrez]
PHST- 2001/07/01 00:00 [pmc-release]
AID - 10.1136/gut.43.2008.s66 [doi]
PST - ppublish
SO  - Gut. 1998 Jul;43 Suppl 1(Suppl 1):S66-9. doi: 10.1136/gut.43.2008.s66.